MnOnanozymes as potential therapeutic agents for autism spectrum disorder: insights from behavioral and molecular studies.

Researchers tested special artificial enzymes called MnOnanozymes in mice with autism-like behaviors. These enzymes are designed to clean up harmful molecules in the brain that may contribute to autism symptoms. The treatment improved social behaviors, reduced repetitive actions, and protected brain cells in the mice. While encouraging, this is very early research and much more testing is needed before considering any human applications.

This preclinical study investigated MnOnanozymes (MnONZs) as potential therapeutic agents for autism spectrum disorder using BTBR mice, an established autism model. The researchers examined whether these artificial enzymes with antioxidant properties could address oxidative stress imbalances associated with ASD. Results demonstrated that MnONZs improved cerebral blood flow, reduced social deficits and repetitive behaviors, enhanced cognitive function, and protected neuronal structure. The nanozymes appeared to work by scavenging reactive oxygen species, reducing neuroinflammation, and mitigating oxidative stress in the hippocampus.

While promising for understanding oxidative stress mechanisms in autism, this remains early-stage research requiring extensive validation before any clinical applications.

This represents very early-stage research into oxidative stress mechanisms in autism. While results suggest potential neuroprotective effects, extensive safety studies, dose optimization, and human trials would be required before any clinical consideration. Current evidence insufficient to inform treatment decisions.

Single preclinical study using animal model; sample size not reported; long-term effects unknown; safety profile not established; significant gap between mouse studies and human autism; unclear translatability of findings to human neurodevelopment.

: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder of uncertain etiology. Current studies suggest that ASD progression is closely linked to an imbalance between oxidative stress and antioxidant capacity, marked by elevated levels of reactive oxygen species (ROS) and reduced concentrations of antioxidant molecules such as superoxide dismutase (SOD) and glutathione (GSH). Although the human body does possess endogenous ROS-scavenging enzymes, their sensitivity to environmental conditions and the difficulties of large-scale production limit their practical application. Consequently, substantial efforts have been dedicated in recent years to developing artificial enzymes with ROS-scavenging activity.

Among these, ROS-scavenging nanozymes have been widely used due to their enhanced stability and multifunctionality. Notably, only a few manganese-containing nanozymes have been reported to exhibit effective reactive oxygen species (ROS) scavenging activity thus far.: In this study, we utilized MnOnanozymes (MnONZs) exhibiting superoxide dismutase, catalase, and hydroxyl radical-scavenging activities. We assessed brain injury, as well as the antioxidative and anti-inflammatory effects of MnONZs through behavioral tests, Nissl staining, immunofluorescence assays, and a laser speckle imaging system. Furthermore, we explored the underlying mechanisms of MnONZs by employing ELISA kits, oxidative stress detection kits, and immunofluorescence analysis.: The results demonstrated that MnONZs increase cerebral blood flow and effectively ameliorate ischemic and hypoxic conditions in BTBR mice.

Moreover, they improve social deficits, repetitive stereotyped behaviors, cognitive impairment, and neuronal morphological damage. Furtherexperiments confirmed that MnONZs exert neuroprotective effects in BTBR mice by mitigating oxidative stress and inflammation.: These findings indicate that MnONZs exhibit excellent antioxidant and anti-inflammatory effectsand effectively enhance cerebral blood flow, ameliorate behavioral deficits, and alleviate neuronal damage in BTBR mice. Collectively, our results suggest that MnONZs exert neuroprotective effects in the hippocampus of BTBR mice by reducing oxidative stress, mitigating neuroinflammation, and rescuing neuronal injury. Consequently, they hold promise as a potential nanomaterial for the treatment of autism.